NASDAQ$DCTH
Delcath Systems Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Delcath reported first quarter results with revenue primarily from CHEMOSAT sales in Europe and is preparing for HEPZATO NDA filing.
Delcath Systems reported first quarter 2022 financial results, with a total revenue of $0.3 million, primarily from CHEMOSAT sales in Europe. The company's net loss was $8.2 million, and they are preparing to file an NDA for HEPZATO in the third quarter of 2022.
- Held a pre-NDA meeting with FDA and plan to file an NDA in Q3 2022.
- Accepted a poster presentation updating results from the FOCUS Phase 3 Trial at ASCO 2022.
- Resumed direct responsibility for sales, marketing, and distribution activities for CHEMOSAT in Europe.
- Achieved medical device regulation (MDR) certification for CHEMOSAT in Europe.
Headline financials
Revenue & EPS history
Delcath · Revenue · Quarterly
$378K
Forward guidance
Delcath is focused on filing the HEPZATO NDA, preparing for the US launch, and expanding clinical development of HEPZATO and CHEMOSAT.
Tailwinds
- Filing of the HEPZATO NDA
- Preparing for the subsequent US launch when approved
- Expanding the clinical development of HEPZATO
- Expanding the clinical development of CHEMOSAT
- Focusing on additional indications of high unmet medical need
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-2.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+7.7%
Avg return
30 days after
28%
9 / 32 earnings
Positive
+37.5%
Q2 2019
Best reaction
-26.4%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +0.6% | -5.3% | |
| Q4 2025 | -11.7% | -15.8% | -12.1% | |
| Q3 2025 | -4.7% | -9.2% | +5.3% | |
| Q1 2025 | +23.6% | +31.7% | +41.1% | |
| Q4 2024 | -1.6% | -12.1% | -18.0% | |
| Q3 2024 | -9.0% | -14.0% | +8.5% | |
| Q2 2024 | -2.6% | -4.2% | +33.7% | |
| Q1 2024 | +33.1% | +40.2% | +37.4% | |
| Q4 2023 | +9.2% | +2.4% | +12.9% | |
| Q3 2023 | -23.7% | -16.9% | +10.0% | |
| Q2 2023 | -20.6% | -23.3% | +18.2% | |
| Q1 2023 | +0.2% | +7.8% | +14.9% | |
| Q4 2022 | +22.3% | +18.8% | +17.6% | |
| Q3 2022 | -6.7% | +0.0% | +11.3% | |
| Q2 2022 | -2.3% | +10.2% | -5.4% | |
| Q1 2022 | -11.9% | -16.7% | -28.1% | |
| Q4 2021 | +1.3% | +2.8% | +0.0% | |
| Q3 2021 | -1.8% | -5.0% | -28.1% | |
| Q2 2021 | -11.8% | -13.5% | +1.1% | |
| Q1 2021 | -7.0% | -0.6% | +9.8% | |
| Q4 2020 | -24.8% | -7.2% | -31.8% | |
| Q3 2020 | +0.6% | +3.6% | +36.7% | |
| Q2 2020 | -2.6% | -4.6% | -9.3% | |
| Q1 2020 | -5.2% | -5.2% | +0.5% | |
| Q4 2019 | +0.0% | +13.8% | +55.7% | |
| Q3 2019 | -4.3% | -4.3% | -15.2% | |
| Q2 2019 | +37.5% | +27.5% | +26.2% | |
| Q1 2019 | -11.2% | +0.0% | +22.5% | |
| Q4 2018 | -6.5% | -8.9% | -35.5% | |
| Q3 2018 | -26.4% | -0.3% | -5.6% | |
| Q2 2018 | +0.0% | +19.0% | +78.8% | |
| Q1 2018 | +2.4% | +0.3% | -0.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro